1. Home
  2. CTNM vs DPG Comparison

CTNM vs DPG Comparison

Compare CTNM & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$13.65

Market Cap

489.4M

Sector

N/A

ML Signal

HOLD

Logo Duff & Phelps Utility and Infrastructure Fund Inc.

DPG

Duff & Phelps Utility and Infrastructure Fund Inc.

HOLD

Current Price

$15.03

Market Cap

529.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTNM
DPG
Founded
2009
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
489.4M
529.2M
IPO Year
2024
2011

Fundamental Metrics

Financial Performance
Metric
CTNM
DPG
Price
$13.65
$15.03
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
512.7K
56.5K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
0.46
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.08
$12.34
52 Week High
$16.91
$15.15

Technical Indicators

Market Signals
Indicator
CTNM
DPG
Relative Strength Index (RSI) 46.54 64.52
Support Level $11.73 $14.06
Resistance Level $14.96 $15.07
Average True Range (ATR) 0.94 0.17
MACD -0.21 0.02
Stochastic Oscillator 7.96 100.00

Price Performance

Historical Comparison
CTNM
DPG

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

About DPG Duff & Phelps Utility and Infrastructure Fund Inc.

Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.

Share on Social Networks: